Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Chinese Participants With Triple-Class Refractory Multiple Myeloma
NCT05228470Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Dec 2021; status: completed.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05228470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228470.